6 - 12 January 2018
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
First PPMS drug licensed
Ocrevus (ocrelizumab) has been licensed by the EU as a treatment for active relapsing and early primary progressive MS. This is the first drug to be licensed for primary progressive MS. Ocrevus will need to be assessed by NICE and SMC before it is available on the NHS
MS Trust link: Ocrevus (ocrelizumab)
Comparison of disease modifying drugs
Swedish research compared six disease modifying drugs for relapsing remitting MS - rituximab, Avonex, Rebif, Copaxone, Gilenya, Tecfidera and Tysabri. People who started on rituximab were less likely to stop or switch drugs. They also had fewer relapses or activity visible on MRI. The article discusses the shortcomings of this type of trial. Rituximab is not available as an MS drug in the UK
Source: MedPage Today
MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing remitting MS